LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation
Author:
Publisher
Elsevier BV
Subject
Pharmacology,General Medicine
Reference46 articles.
1. Cancer statistics, 2017;Siegel;CA. Cancer. J. Clin.,2017
2. Cisplatin in cancer therapy: molecular mechanisms of action;Dasari;Eur. J. Pharmacol.,2014
3. Systems biology of cisplatin resistance: past, present and future;Galluzzi;Cell Death Dis.,2014
4. Cisplatin cross-linked multifunctional nanodrugplexes for combination therapy;Zhang;ACS Appl. Mater. Interfaces,2017
5. Interactions of cisplatin with non-DNA targets and their influence on anticancer activity and drug toxicity: the complex world of the platinum complex;Mezencev;Curr. Cancer Drug Targets,2015
Cited by 135 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy;Drug Resistance Updates;2024-03
2. MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting;Pathology - Research and Practice;2024-01
3. Advances in long non-coding RNA regulating drug resistance of cancer;Gene;2023-12
4. Comprehensive landscape and future perspective of long noncoding RNAs in non-small cell lung cancer: it takes a village;Molecular Therapy;2023-12
5. Long non-coding RNA and Evolving drug resistance in lung cancer;Heliyon;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3